Table 1 Number of cases in each group and the main FNAC and histopathological diagnoses

Group 1: Insufficient (n = 12/8334; 0.1%)

Group 1 (n = 0; 0,0%)

Group 2: Benign (n = 7384/8334; 88.6%)

 Cyst (n = 3477; 47.0%)

 PBDWA (n = 1400; 19.0%)

 Fibroadenoma (n = 1227; 16.6%)

 Others (n = 1286; 17.4%)

Group 2: 250

Benign (n = 244/250; 97.6%)

 Fibroadenoma (n = 72)

 FBD (n = 69)

 Cyst (n = 52)

 Others (n = 51)

Malignant (n = 6/250; 2.4%)

 IBC (n = 2)

 Tumor phyllodes, ILC, DCIS (n = 4)

Group 3: Atypical, probably benign

(n = 402/8334; 4.8%)

Group 3: 214

Benign (n = 170/214; 79.4%)

 FBD (n = 83)

 P (n = 47)

 Fibroadenoma (n = 29)

 Others (n = 11)

Malignant (n = 44/214; 20.6%)

 DCIS (n = 19)

 IBC (n = 17)

 Others (n = 8)

Group 4:: Suspicious, probable in situ

or invasive carcinoma

(n = 140/8334; 1.7%)

Group 4: 95

Benign (n = 27/95; 28.4%)

 FBD (n = 16)

 Fibroadenoma (n = 7)

 P (n = 4)

Malignant (n = 68/95; 71.6%)

 IBC (n = 41)

 DCIS (n = 11)

 ILC (n = 8)

 Others (n = 8)

Group 5: Malignant

(n = 396/8334; 4.8%)

Group 5: 226

Benign (n = 1/226; 0.4%)

 Fatty necrosis (n = 1)

Malignant (n = 225/226; 99.6%)

 IBC (n = 186)

 ILC (n = 23)

 Others (n = 34)